Discover critical updates from Vertex Pharmaceuticals Inc. in their 8-K report filed on May 5, 2025. Key insights on stock and company performance included.
Explore Vertex Pharmaceuticals' Q4 2024 financial report revealing $11B in revenue, but a net loss of $536M. Key insights on R&D spending and market position.
Explore Vertex Pharmaceuticals Inc.'s 8-K report filed on February 4, 2025. Key updates on regulations, trading, and corporate compliance for VRTX investors.
Explore Vertex Pharmaceuticals' 8-K filing dated December 20, 2024, detailing significant corporate events. Find essential information for investors and analysts in this report.